Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A gynecologic oncology group study

Matthew A. Powell, Virginia L. Filiaci, Peter G. Rose, Robert S. Mannel, Parviz Hanjani, Koen DeGeest, Brigitte E. Miller, Nobuyuki Susumu, Frederick R. Ueland

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Purpose: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor). Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through the Gynecologic Oncology Group. However, the toxicity, multiday schedule, and limited activity of this regimen support further development of novel regimens. Our primary objective was to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas. Patients and Methods: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy. Patients received paclitaxel at 175 mg/m2 intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred. Common Terminology Criteria for Adverse Events v3.0 was used to grade adverse events. Results: Fifty-five patients were entered onto the study with nine being excluded from analysis, leaving 46 evaluable for analysis. Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy. The proportions of patients with confirmed complete and partial responses were 13% and 41%, respectively, resulting in a total overall response rate of 54% (95% CI, 37% to 67%). Conclusion: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.

Original languageEnglish
Pages (from-to)2727-2731
Number of pages5
JournalJournal of Clinical Oncology
Volume28
Issue number16
DOIs
Publication statusPublished - 2010 Jun 1
Externally publishedYes

Fingerprint

Carcinosarcoma
Carboplatin
Paclitaxel
Uterus
Therapeutics
Malignant Mixed Tumor
Platinum Compounds
Drug Therapy
Ifosfamide
Terminology
Disease Progression
Appointments and Schedules
Pain
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus : A gynecologic oncology group study. / Powell, Matthew A.; Filiaci, Virginia L.; Rose, Peter G.; Mannel, Robert S.; Hanjani, Parviz; DeGeest, Koen; Miller, Brigitte E.; Susumu, Nobuyuki; Ueland, Frederick R.

In: Journal of Clinical Oncology, Vol. 28, No. 16, 01.06.2010, p. 2727-2731.

Research output: Contribution to journalArticle

Powell, MA, Filiaci, VL, Rose, PG, Mannel, RS, Hanjani, P, DeGeest, K, Miller, BE, Susumu, N & Ueland, FR 2010, 'Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A gynecologic oncology group study', Journal of Clinical Oncology, vol. 28, no. 16, pp. 2727-2731. https://doi.org/10.1200/JCO.2009.26.8326
Powell, Matthew A. ; Filiaci, Virginia L. ; Rose, Peter G. ; Mannel, Robert S. ; Hanjani, Parviz ; DeGeest, Koen ; Miller, Brigitte E. ; Susumu, Nobuyuki ; Ueland, Frederick R. / Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus : A gynecologic oncology group study. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 16. pp. 2727-2731.
@article{dd2e6b02986d441784ae01da69814730,
title = "Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A gynecologic oncology group study",
abstract = "Purpose: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor). Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through the Gynecologic Oncology Group. However, the toxicity, multiday schedule, and limited activity of this regimen support further development of novel regimens. Our primary objective was to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas. Patients and Methods: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy. Patients received paclitaxel at 175 mg/m2 intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred. Common Terminology Criteria for Adverse Events v3.0 was used to grade adverse events. Results: Fifty-five patients were entered onto the study with nine being excluded from analysis, leaving 46 evaluable for analysis. Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59{\%} of patients completing six or more cycles of chemotherapy. The proportions of patients with confirmed complete and partial responses were 13{\%} and 41{\%}, respectively, resulting in a total overall response rate of 54{\%} (95{\%} CI, 37{\%} to 67{\%}). Conclusion: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.",
author = "Powell, {Matthew A.} and Filiaci, {Virginia L.} and Rose, {Peter G.} and Mannel, {Robert S.} and Parviz Hanjani and Koen DeGeest and Miller, {Brigitte E.} and Nobuyuki Susumu and Ueland, {Frederick R.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1200/JCO.2009.26.8326",
language = "English",
volume = "28",
pages = "2727--2731",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus

T2 - A gynecologic oncology group study

AU - Powell, Matthew A.

AU - Filiaci, Virginia L.

AU - Rose, Peter G.

AU - Mannel, Robert S.

AU - Hanjani, Parviz

AU - DeGeest, Koen

AU - Miller, Brigitte E.

AU - Susumu, Nobuyuki

AU - Ueland, Frederick R.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Purpose: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor). Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through the Gynecologic Oncology Group. However, the toxicity, multiday schedule, and limited activity of this regimen support further development of novel regimens. Our primary objective was to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas. Patients and Methods: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy. Patients received paclitaxel at 175 mg/m2 intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred. Common Terminology Criteria for Adverse Events v3.0 was used to grade adverse events. Results: Fifty-five patients were entered onto the study with nine being excluded from analysis, leaving 46 evaluable for analysis. Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy. The proportions of patients with confirmed complete and partial responses were 13% and 41%, respectively, resulting in a total overall response rate of 54% (95% CI, 37% to 67%). Conclusion: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.

AB - Purpose: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor). Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through the Gynecologic Oncology Group. However, the toxicity, multiday schedule, and limited activity of this regimen support further development of novel regimens. Our primary objective was to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas. Patients and Methods: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy. Patients received paclitaxel at 175 mg/m2 intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred. Common Terminology Criteria for Adverse Events v3.0 was used to grade adverse events. Results: Fifty-five patients were entered onto the study with nine being excluded from analysis, leaving 46 evaluable for analysis. Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy. The proportions of patients with confirmed complete and partial responses were 13% and 41%, respectively, resulting in a total overall response rate of 54% (95% CI, 37% to 67%). Conclusion: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=77954948152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954948152&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.26.8326

DO - 10.1200/JCO.2009.26.8326

M3 - Article

C2 - 20421537

AN - SCOPUS:77954948152

VL - 28

SP - 2727

EP - 2731

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -